Threshold Pharmaceuticals Reports Second Quarter Financial Results
01. August 2016 08:00 ET
|
Threshold Pharmaceuticals, Inc.
-- Presented additional subset data at ASCO from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer; meaningful improvement in overall survival in patients from Asia -- SOUTH SAN FRANCISCO,...
Threshold Pharmaceuticals Highlights Multiple Presentations at the 2016 ASCO Annual Meeting
06. Juni 2016 08:30 ET
|
Threshold Pharmaceuticals, Inc.
CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced multiple presentations on clinical trials on its hypoxia-activated prodrugs, evofosfamide and...
Threshold Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference
01. Juni 2016 08:30 ET
|
Threshold Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold’s Chief Executive Officer, will...
Threshold Pharmaceuticals Reports First Quarter Financial Results
05. Mai 2016 16:02 ET
|
Threshold Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today...
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
21. März 2016 08:00 ET
|
Threshold Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer,...
Threshold Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results
10. März 2016 16:05 ET
|
Threshold Pharmaceuticals, Inc.
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon...
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cowen and Company 36th Annual Health Care Conference
01. März 2016 07:00 ET
|
Threshold Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold’s Chief Executive Officer, will...
Threshold Pharmaceuticals Provides Update on Continued Promising Data From a Phase 1/2 Clinical Trial of TH-302 at the American Society of Clinical Oncology Annual Meeting
06. Juni 2011 08:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...
Threshold Pharmaceuticals Reports First Quarter 2011 Financial and Operational Results
12. Mai 2011 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the first quarter ended March 31, 2011.
The net loss for...
Threshold to Present at the 10th Annual JMP Securities Research Conference
09. Mai 2011 08:30 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 9, 2011 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the 10th...